跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 6,298 条关于
“ETA-067”
全部
6,298
临床试验
3,784
药物
1,586
机构
116
资讯
812
去年
Novel Evobody Bispecific Antibodies Show Promise in Ovarian Cancer by Targeting Vγ9Vδ2 T Cells
去年
Simcha Therapeutics Launches Clinical Trials of ST-067 in Hematological Cancers
2年前
CheckMate 067: Nivolumab Plus Ipilimumab Shows Sustained Survival Benefit in Advanced Melanoma at 10 Years
2年前
Opdivo and Yervoy Combination Shows Durable Survival Benefit in Advanced Melanoma After 10 Years
11个月前
Simcha Therapeutics Reports Enhanced Cancer Treatment Efficacy with Decoy-Resistant IL-18 and Bispecific T-Cell Engagers
去年
BioCity's SC0062 Receives Breakthrough Therapy Designation for IgA Nephropathy
去年
BioCity's SC0062 Receives Second Breakthrough Therapy Designation for Diabetic Kidney Disease Treatment
去年
Atrasentan Receives FDA Accelerated Approval for IgA Nephropathy After Decades-Long Development Journey
2年前
Nivolumab and Ipilimumab Combination Shows Durable 10-Year Survival Benefit in Advanced Melanoma
2年前
Long-Term Data Show Durable Benefit of Immunotherapy in Metastatic Melanoma
第 1 页,共 82 页
上一页
下一页